Aprogen Biologics Inc.

Equities

A003060

KR7003060001

Pharmaceuticals

End-of-day quote Korea S.E. 07:00:00 2024-03-25 pm EDT 5-day change 1st Jan Change
1,900 KRW -4.52% Intraday chart for Aprogen Biologics Inc. -5.94% -34.48%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Aprogen Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Aprogen Biologics Inc.(KOSE:A003060) dropped from S&P Global BMI Index CI
Aprogen Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Aprogen Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Aprogen Biologics Inc. announced that it has received KRW 20 billion in funding from Aprogen, Inc. CI
Aprogen Biologics Inc. announced that it expects to receive KRW 20 billion in funding from Aprogen, Inc. CI
Aprogen Biologics Inc. announced that it has received KRW 40 billion in funding CI
Aprogen Biologics Inc. announced that it expects to receive KRW 40 billion in funding CI
Aprogen Biologics Inc. announced that it has received KRW 40.0000005 billion in funding from Aprogen Medicines Inc. CI
Aprogen pharmaceuticals,Inc. completed the acquisition of Aprogen Biologics Inc. from Aprogen, Inc. CI
Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Aprogen Pharmaceuticals to Raise $35.1 Million Through Stock Issuance MT
Aprogen pharmaceuticals,Inc. agreed to acquire Aprogen Biologics Inc. from Aprogen, Inc. CI
Aprogen Biologics Inc. announced that it expects to receive KRW 50 billion in funding from Aprogen Medicines Inc. CI
Aprogen pharmaceuticals,Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Aprogen pharmaceuticals,Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Aprogen pharmaceuticals,Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Aprogen pharmaceuticals,Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Aprogen Medicines Inc. announced that it expects to receive KRW 105 billion in funding from Korea Fixed Income Investment Advisory Co., Ltd., Aprogen pharmaceuticals,Inc., Aprogen Healthcare & Games Inc. CI
Immunotech Biopharm : Hires Aprogen Director as New Tech Chief MT
Aprogen KIC Inc. cancelled the acquisition of additional 5.6% stake in Aprogen pharmaceuticals,Inc.. CI
Aprogen KIC Inc. agreed to acquire additional 5.6% stake in Aprogen pharmaceuticals,Inc. for KRW 17.8 billion. CI
Aprogen pharmaceuticals,Inc. acquired an additional 6.38% stake in Locojoy International Corporation from Aprogen Biologics Inc. for KRW 7 billion. CI
Aprogen pharmaceuticals,Inc. announced that it has received KRW 20.000000214 billion in funding from Aprogen KIC Inc. CI
Chart Aprogen Biologics Inc.
More charts
Aprogen Biologics Inc, formerly Aprogen Pharmaceuticals Inc, is a Korea-based company principally engaged in the pharmaceutical business. The Company operates its business through two segments. The Medicine Business segment is engaged in the manufacture and sale of central nervous system drugs, autonomic agents, arteriosclerosis agents, metabolic agents, circulatory system drugs, biopharmaceuticals and others. The Segment is also engaged in the manufacture and sale of cosmetics such as skin moisturizers and others. The Gaming Business segment is engaged in the development and operation of role-playing games (RPGs).
More about the company
  1. Stock
  2. Equities
  3. Stock Aprogen Biologics Inc. - Korea S.E.
  4. News Aprogen Biologics Inc.
  5. Aprogen Pharmaceuticals to Raise $35.1 Million Through Stock Issuance